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POLYMORPHISMS IN THE IL-12 AND IL-12R GENES: ALTERING PLASMODIUM 
FALCIPARUM DISEASE OUTCOME 
LaToya Michelle Strong, M.S. 
 University of Pittsburgh, 2009 
 
Malaria is a major public health concern as greater than 40% of the world’s population is 
at risk. Globally and annually, there are approximately 300-500 million incident cases a year 
resulting in between 1 and 2 million deaths; the majority of these deaths occur in children under 
the age of 5 and in pregnant women. There are several disease complications that can arise from 
malaria, two of which are high density parasitemia (HDP) and severe malaria anemia (SMA). 
Not everyone who gets malaria gets HDP or SMA, and the underlying reason for this is 
unknown, however, research has shown that innate immune mediators, including Interleukin-12 
(IL-12), play an important role.  Currently there is no vaccine for malaria and drug resistance is a 
major issue. This study is of public health significance because it can give insight into the 
difference between those individuals who progress to severe disease complications and those that 
do not; potentially giving rise to novel drug and vaccine development. The severity and 
occurrences of these complications vary by age, region, and level of malaria endemicity. 
Previous studies have indicated a role for not only circulating levels of IL-12, but also for 
polymorphisms in the IL-12 and Interleukin-12 Receptor (IL-12R) genes. To gain a better 
understanding of the role that polymorphisms in the IL-12 and IL-12R genes may have we 
conducted a case-control study to compare phenotypic data to genotypic data. We investigated 
four Single Nucleotide Polymorphisms (SNPs) - rs2243113, rs2243140, rs383483 and rs429774 
- in the IL-12 and IL-12R genes to determine if a correlation existed between disease status and 
v 
genotype. We found that for all four SNPs, there was not a correlation between disease status and 
genotype. We also investigated the distribution of these four SNPs across populations with 
varying malaria endemicity. We also found that in all of the populations except for the Kenyan 
population there is a higher frequency of homozygous wildtype alleles for both rs2243113 and 
rs2243140 and a higher frequency of heterozygotes for rs383483.  
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PREFACE 
“Piglet sidled up to Pooh from behind. “Pooh,” he whispered. 
“Yes, Piglet?” 
“Nothing,” said Piglet, taking Pooh’s paw, “I just wanted to be sure of you” 
-Winnie the Pooh 
 
"Here's to the crazy ones, the misfits, the rebels, the troublemakers, the round pegs in a square 
hole, the ones who see things differently. They're not fond of rules, and they have no respect for 
the status quo. You can quote them, disagree with them, glorify or vilify them. About the only 
thing you can't do is ignore them, because they change things. They push the human race 
forward, and while some may see them as the crazy ones, we see genius, because the people who 
are crazy enough to think they can change the world, and are the ones who'll do it." 
            - Apple Computer TV Ad 
 
"Be daring, be different, be impractical, be anything that will assert integrity of purpose and 
imaginative vision against the play-it-safers, the creatures of the commonplace, the slaves of the 
ordinary." 
  - Sir Cecil Beaton 
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1.0  INTRODUCTION 
 
1.1 DESCRIPTION OF THE PROBLEM 
Globally, there are 300 – 500 million incident cases of malaria each year resulting in 
approximately 1 million deaths. Most of these deaths occur in children under the age of 5 and 
pregnant women [1]. Malaria is a disease of impoverished countries as well as tropical countries, 
particularly sub-Saharan Africa [2, 3] There are several complications that can arise following a 
malaria infection. These complications include, but are not limited to, cerebral malaria (CM), 
severe malaria anemia (SMA) and high density parasitemia (HDP) [4]. The clinical 
manifestations of these complications vary by age, region, and level of endemicity [5].  
Currently there is no vaccine for malaria, and drug resistance to anti-malarials has become a 
global problem [6]. Drugs that were at the forefront of malaria treatment, such as Chloroquine 
and, increasingly, sulphadoxine-pyrimethamine (SP), have become ineffective as single drug 
treatments because of resistance. The World Health Organization (WHO) now recommends 
artemisinin-based combination therapy (ACT) as a first line of treatment for malaria.  Although 
it is very efficacious, it is too costly for some countries.   [7].  
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Many studies have illustrated the importance of cytokines such as interleukin (IL)-12, and 
interferon-gamma (IFN-γ) in the immune response to malaria infection. These cytokines are 
initially produced by innate immune cells such as dendritic cells (DCs) and macrophages. 
Studies looking at these cytokines have shown that individuals with higher levels of IL-12, IFN-
γ, and other innate immune mediators have a strong correlation with lower rates of severe disease 
complications [3, 8]. In addition to looking at plasma levels or circulating levels of cytokines, 
previous studies have demonstrated that host genetics plays a major role in the development of 
malaria disease outcomes. It has been shown that polymorphisms in cytokine genes can be 
determinants of malaria disease outcome [9, 10]. 
 This study also addresses the role that polymorphisms in immune mediators may have in 
malaria disease outcome. This study like the ones before it addresses an important issue; what is 
the difference between individuals who develop complications and those who are able to fight 
off the disease. As more understanding is gained about the pathogenesis of malaria and the role 
that host genetics plays, more options are gained for drug development.  
1.2 MALARIA 
Malaria is caused by single celled protozoan parasites of the Plasmodium genus [11]. There are 
four Plasmodium species, malariae, ovale, vivax and falciparum. Plasmodium ovale is found in 
Western Africa and is the least severe. Similar to P. ovale, P. malariae has low frequency of 
infection; however, it is distributed worldwide. P. vivax is the most widespread species, but it is 
rarely fatal. P. falciparum can be attributed to most of the mortality associated with malaria [12]. 
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This thesis will focus on P. falciparum. Malaria is a vector-borne disease transmitted by the bite 
of a female anopheline mosquito. There are three stages to the parasite life cycle: the mosquito 
stage, the human liver stage, and the human blood stage [12]. The bite of an infected female 
mosquito injects sporozoites into the host. The sporozoites are then quickly transported through 
the blood to the liver beginning the liver stage of the life cycle. In the liver the sporozoites 
mature and undergo asexual replication, known as exo-erythrocytic schizogony, forming 
schizonts. [11] The schizonts eventually burst releasing thousands of merozoites, which 
immediately invade host red blood cells [13]. This marks the beginning of the human blood 
stage. This stage is extremely important because it is where the clinical manifestations of the 
disease appear. The merozoites mature and undergo asexual reproduction to form erythrocytic 
schizonts, each containing daughter merozoites. These merozoites can do one of two things. 
They can re-infect red blood cells forming a cyclical blood stage infection or differentiate into 
male and female gametocytes which are taken up by a mosquito. [11, 13] Once the gametocytes 
are taken up the beginning of the third stage of the life cycle, the mosquito stage begins. In the 
mosquito the gametocytes give rise to gametes which subsequently develop into sporozoites 
[13].  The three stages of the malaria life cycle can be seen in Figure 1. 
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Figure 1. Malaria Life Cycle [11]. 
Copyright Permissions Granted 
 
 A characteristic of infection that occurs in P. falciparum malaria, but not in the other 
Plasmodium species is sequestration. Sequestration is the accumulation of large numbers of 
parasitized erythrocytes in various organs [14]. Infected erythrocytes (IE) containing young 
forms of the parasite are able to circulate freely, but on the contrary, IEs infected with more 
mature forms of the parasite are bound to endothelial cells and are subsequently sequestered 
away from peripheral circulation [13].  
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1.2.1 MALARIA DISEASE COMPLICATIONS 
A malaria infection can lead to many disease complications, two of which are High density 
parasitemia (HDP) and Severe malaria anemia (SMA) [3]. Parasitemia is measured by the 
number of parasites (P) per liter of blood (P/L) and malaria anemia is expressed as grams of 
hemoglobin per dL of blood (g/dL). A table representing the hemoglobin and parasitemia levels 
for each respective disease outcome that was used in this study can be seen in Table 1 and Table 
2, respectively. SMA and HDP are important because these complications are seen most often in 
children under the age of 5 and pregnant women. These groups also have the highest malaria 
mortality rate [15].  
Although the underlying cause of these outcomes are not currently known, research has 
shown that the production of innate inflammatory mediators plays an important role [11], [16].  
Intereukin-12 (IL-12), a  major pro-inflammatory cytokine, is important in the immune response 
to malaria is IL-12 exerts immunoregulatory effects on T-cells and natural killer (NK) cells as 
well as inducing a Type-1 T Helper (TH1) response [9]. 
 
Table 1.  Classification for Malaria Anemia Clinical Disease Status 
Classifications of Malaria Anemia Status 
Hemoglobin Level (g/dL of blood) Clinical Disease Status 
≥ 11 Non-Anemic (NA) 
8.0 – 10.9 Mild Malaria Anemia (milMA) 
6.0 – 7.9 Moderate Malaria Anemia (modMA) 
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Table 1: Continued 
Hemoglobin Level (g/dL of blood) Clinical Disease Status 
<6 Severe Malaria Anemia (SMA) 
 
Table 2. Classification of Parasitemia Clinical Disease Status 
Classifications of Parasitemia Status 
Parasitemia Level (P/L of blood) Clinical Disease Status 
0 Aparasitemic Controls (APs) 
< 10,000 Low Density Parasitemia (LDP) 
≥ 10,000 High Density Parasitemia  (HDP) 
 
1.3 INTERLEUKIN-12 
Cytokines are small proteins released by immune cells upon activation.  Upon release, cytokines 
induce responses when bound to their receptors. Cytokines can act in an autocrine, paracrine or 
endocrine manner, meaning they can affect the behavior of the cell that released it, an adjacent 
cell, or a distant cell, respectively [17]. Interleukin-12 or IL-12p70 (IL-12) is a 70 kDa, 
heterodimeric, proinflammatory, cytokine produced by phagocytic cells. IL-12 is made up of a 
35 kDa light chain and a 40 kDa heavy chain termed p35 and p40, respectively. The p35 subunit 
is also referred to as IL-12A or IL-12α and the p40 subunit is also referred to as IL-12B or IL-
12β. The p35 and p40 subunits are linked by two disulfide bonds [18]. The genes encoding the 
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p35 and p40 subunit are located on different chromosomes and protein expression is therefore 
regulated independently. The p35 subunit is found on chromosome 5q31-33 and p40 is found on 
3p12-3q13.2. [19] Both the p35 and p40 subunit must be expressed coordinately in the same cell 
to form the bioactive IL-12p70 [18]. IL-12α or p35 is expressed ubiquitously and constitutively 
at low levels and the p40 subunit is limited to expression in phagocytic cells. IL-12α serves as 
the rate limiting factor in the expression of IL-12 because IL-12βis always made in excess of IL-
12α. IL-12α is regulated both transcriptionally and translationally, whereas IL-12β is only 
regulated transcriptionally [20]. 
IL-12 is produced by antigen presenting cells (APCs) and phagocytic cells, which include 
monocytes/macrophages, dendritic cells (DCs), neutrophils, and to a lesser extent, B-cells [20] 
[18] [21]. The major IL-12 responders are natural killer (NK) cells and activated T-cells. The 
effects that IL-12 has on both these cells are to induce proliferation and IFN-γ production, 
increase cytotoxicity activity, and polarize undifferentiated T cells to a TH1 response [20]. A 
picture depicting the sources, responders and functions of IL-12 can be seen in Figure 2.  In 
addition to the immunoregulatory effects that IL-12 has on T cells and NK cells, IL-12 has 
several other effects on the immune response. Not only does IL-12 induce the production of IFN-
γ by T-cells and NK-cells, IL-12 itself also produces IFN-γ. A positive feedback loop exists 
between IL-12 and IFN-γ in which IL-12 secretes IFN-γ, which in turn primes monocytes and 
peripheral mononuclear blood cells (PMNCs), which in turn produces more IL-12. [20] A 
schematic of the overall biology of IL-12 can be seen in Figure 3. 
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Figure 2. IL-12 producers, responders and functions [20]. 
Copyrights Permissions Granted  
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Figure 3. Overall Biology of IL-12 [18]. 
Copyright Permissions Granted. 
 
The IL-12 receptor (IL-12R) is composed of two chains: IL12-Rβ1 (β1) and IL12-R (β2). 
These subunits activate the Janus Kinase – Signal Transducer and Activator (JAK-STAT) 
pathway [18]. The β1 and β2 subunits are found on separate chromosomes, β1on 19p13.1 and B2 
on 1p31.2, and are therefore independently regulated. β1, which is predominately used for ligand 
binding, interacts with the p40 subunit of IL-12. Unlike β1, β2 has tyrosine residues and is 
therefore used as the signal transducing chain of the receptor. β2 interacts with the p35 chain of 
IL-12. [20] Co-expression of both subunits is required for high affinity IL-12 binding sites. Both 
the B1 and B2 subunits are type-I transmembrane glycoproteins with molecular weights of 100 
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kDa and 130 kDa, respectively [22]. The IL-12 receptors are found on NK cells and activated T 
cells. 
 
1.4 TYPE 1 T HELPER CELL RESPONSE 
 
Type-I T Helper (TH1) cells are important cells in the immune response to malaria. Upon 
activation, naïve CD4+ T cells can differentiate into either TH1 or TH2 cells. TH1 cells leads to 
cell-mediated immunity and TH2 leads to humoral immunity [23]. Humoral immune responses 
are mediated by antibody production by B-cells and cell-mediated immunity is mediated by 
antigen specific T-cells [17]. Specific cytokine profiles present at the beginning stages of CD4+ 
T Cells are determining factors for polarization towards a TH1 or TH2 response. IL-4, IL-5 and 
IL-6 are thought to be the TH2 polarizing cytokines and IL-2 and IL-12 are thought to be the TH1 
polarizing cytokines [24]. IL-12Rβ2 is thought to be the determinant of TH phenotype because 
both the β1 and β2 receptors are present on TH1cells but β2 expression is lost in TH2 cells [20], 
[24]. A TH1 immune response presupposes an effective fight against intracellular pathogens [23] 
and is therefore important in the body’s fight against malaria. A TH1 response is characterized by 
the production of interferon-gamma (IFN-γ), interleukin (IL)-2 and tumor necrosis factor-beta 
(TNF-β). TNF-β and IFN-λ both recruit and activate inflammatory cytokines [25].  A schematic 
of factors involved in the TH1 differentiation can be seen in Figure 4. 
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Figure 4. TH1 differentiation [18]. 
Copyright Permissions Granted. 
 
1.5 SINGLE NUCLEOTIDE POLYPORPHISMS 
Single nucleotide polymorphisms (SNPs) are single base pair changes in the genome that occur 
every 300-1000 bases. SNPs account for 90% of the genetic variation that exists in humans. In 
order for a single base pair mutation to be considered a SNP, it must occur in at least 1% of the 
population. SNPs are important for several reasons. They can affect how the body responds to a 
specific drug, they can affect how the body responds to an infection, and SNPs can be markers 
for diseases. A single SNP can also cause a disease such as in the case of Sickle Cell Anemia.  
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1.6 PREVIOUS STUDIES 
Many studies have been done to show the significance of IL-12 and a TH1 response in the 
immune response to malaria. Malaguarnera et al. (2002) did a study in which they measured the 
plasma level of IL-12 in a group of 73 children and correlated that level with the severity of the 
disease. They found that IL-12 levels were significantly elevated in children with less severe 
disease. They also found that the level of IL-12 was significantly lower in patients with more 
severe disease. Patients with lower levels of IL-12 showed more severe anemia, lower platelet 
count, and higher levels of parasite density. [3] 
Moreover, studies have also been done to show the influence that SNPs in the IL-12 gene 
may have in malaria disease outcome. McGuire et al. showed that homozygotes for a variant in 
the tumor necrosis factor-α (TNF-α) had an increased risk for developing CM [10]. Although this 
study did not focus on IL-12 it was important because it was the first to show a relationship 
between a cytokine gene polymorphism and a malaria disease outcome. The study that 
specifically influenced our study hypothesis used 75 tagging SNPs that covered the p35, p40, β1 
and β2 genes for IL-12 and IL-12R, respectively. They found a correlation between susceptibility 
to SMA and SNPS rs2243140 and rs2243133. They also found a correlation between a 
protection from SMA and SNPs rs383483 and rs429774 as well as a protection against HDP in 
rs383483. This study is the basis for why we chose to use these SNPs in this study. 
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2.0  MATERIALS AND METHODS 
 
2.1 STUDY OVERVIEW 
For this study, we wanted to analyze four single nucleotide polymorphisms (SNPs), two in the 
gene encoding the p35 subunit of IL-12 and two in the gene encoding the β1 subunit of the IL-12 
receptor.  The specific SNP and its location, effect, and nucleotide change can be seen in Table 3 
below. We wanted to investigate a possible correlation between these SNPs and malaria disease 
outcome. The disease outcomes that we were investigating were severe malaria anemia (SMA) 
and High density parasitemia (HDP). To do this, we conducted a blinded case-control study; 
phenotype data was revealed only after samples were genotyped. We used fluorescent 
polarization (FP) to genotype the samples. After all samples were genotyped we then did the 
Hardy-Weinberg Equilibrium and chi-squared statistical tests to see if the overall genotype 
distribution was out of equilibrium. We then stratified our data by disease status to see if the 
genotype distribution was in Hardy-Weinberg equilibrium. 
 We then wanted to investigate differences existing in the distribution of the genotypes of 
the SNPs throughout different regions of the world. In addition to our Kenyan pediatric 
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population, we also looked at a group from Bogoin Village in Central African Republic, two 
regions of Papua New Guinea, and four tribes of Madagascar. Furthermore, we also took 
information from the International HapMap Project to compare our samples with. The 
populations used from HapMap are the Yoruba in Ibadan, Nigeria (YRI), the Japanese in Tokyo, 
Japan (JPT), the Han Chinese in Beijing, China (CHB), and the CEPH Collection [(Utah 
Residents with Northern and Western European Ancestry)CEU] [26]. 
 
 
Table 3. Description of SNPs used in the Study 
SNP Nucleotide 
Change 
Gene Location Associated 
Effect 
Associated Disease 
Outcome 
rs2243113 A/G IL-12A Promotor Susceptibility SMA 
rs2243140 T/C IL-12A 3’ UTR Susceptibility SMA 
rs383483 G/A IL-12Rβ1 Intron Protective HDP 
rs383483 G/A IL-12Rβ1 Intron Protective SMA 
rs429774 T/C IL-12Rβ1 Intron Protective SMA 
UTR – Untranslated Region; SMA – Severe Malaria Anemia; HDP – High Density Parasitemia 
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2.2 HYPOTHESIS 
For the SNPs associated with disease susceptibility, rs2243113 and rs2243140, we expected to 
see a higher frequency of the homozygous mutant genotype and a deviation from the Hardy-
Weinberg Equilibrium (HWE) in individuals with the more severe disease complication. 
For the SNPs associated with disease protection, rs383483 and rs429774, we expected to 
see a higher frequency of the homozygous mutant genotype and a deviation from the HWE in 
individuals with the less severe disease complications.  
For the haplotype data, we expected to see higher frequency of at least one haplotype that 
is more prevalent in the non-SMA groups and not in the SMA disease group or vice versa.  
Geographically, we expected to see higher rates of homozygous mutant protective 
genotypes in a deviation from HWE in populations with higher rates of malaria transmission.  
2.3 STUDY POPULATIONS 
2.3.1 KENYAN POPULATION  
Children less than three years of age (n=650) who presented at the hospital with acute malaria or 
for routine immunizations were recruited to the study. All participants were from the Luo ethnic 
group. Children with detectable P. falciparum parasitemia were categorized into two groups 
depending on their anemia status: non-SMA (Hb ≥ 6.0 g/dL , n=309) and SMA (Hb < 6.0 g/dL, 
n=210). The definition of SMA was based on the distribution of anemia determined by > 14,000 
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longitudinal Hb measurements in age and gender matched children from the same geographic 
area. Aparasitemic controls (APs, n=124) were children with P. falciparum parasitemia negative 
blood smears, free from fever or other related malaria symptoms in the two weeks prior to 
enrollment. Exclusion criteria were co-infection with other Plasmodium species, prior 
hospitalizations, a blood transfusion for any reasons, and CM [Awandare, unpublished data]. It 
should be noted that the patient status of SMA, non-SMA, and APs were not known by us prior 
to data collection. Although the total sample size is 650, the sample size used to analyze the data 
of each SNP was much less because of missing data, no data collection, or problems with 
genotype calling. 
2.3.2 CENTRAL AFRICAN REPUBLIC, MADAGASCAR, PAPUA NEW 
GUINEA 
We wanted to investigate the geographic distribution of the four SNPs under investigation across 
several populations. The populations used for this part of the study included  sample groups from 
Bogoin Village in Central African Republic, two regions of Papua New Guinea (Kavieng and 
Madang) and four  tribes of Madagascar (Betsileo, Bezanozano, Merina and Sihanaka). These 
samples were taken as part of an anthropological study; therefore information on malaria disease 
status is unknown. The total sample size for each population can be seen in Table 4. 
Table 4. Sample Size For Each Population 
Total Sample Sizes For Each Population 
Population Sample Size 
Betsileo 42 
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Table 4: Continued 
Population Sample Size 
Merina 42 
Bezanozano 17 
Sihanaka 19 
Bogoin Village 52 
Kavieng 31 
Madang 65 
 
 
2.3.3 HAPMAP DATABASE 
 
HAPMAP is an online database of common genetic variants that occur in human beings. 
Furthermore, we also took information from the International HapMap Project. The populations 
used from HapMap are the Yoruba in Ibadan, Nigeria (YRI), the Japanese in Tokyo, Japan 
(JPT), the Han Chinese in Beijing, China (CHB), and the CEPH Collection [(Utah Residents 
with Northern and Western European Ancestry)CEU] [26]. 
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2.4 DNA SAMPLE QUANTIFCATION 
To quantify the concentration of DNA in each sample we used the PicoGreen assay, which is a 
dye based assay used to quantify double stranded (ds) DNA. To quantify our DNA we used the 
Invitrogen Quant-iT™ PicoGreen® Kit. First, 99 µL of 1X TE buffer was added to each well of 
a 96-well microtitre plate followed by adding one 1 µL of the DNA sample. We then constructed 
standard curves by serial dilutions of lambda (λ) DNA stock. λ DNA was prepared by diluting 
the stock solution 1:50 in TE buffer, making enough for three replicate reads. 
Table 5. Lambda DNA dilution 
(λ) DNA (µL) TE buffer (µL) Final Volume (µL) 
         12      588           600 
 
 
We then added the dilutions shown in Table 5 in triplicate to a 96-well microtitre plate. 
The average of the three readings was the standard to which our DNA samples were compared. 
The TE buffer was added first and then the λ DNA was added. The following table depicts the 
serial dilutions (Table 6). These dilutions were used to create the standard curve.  
Table 6. λ DNA Serial Dilutions Used to Make Standard Curve 
Volume of λ DNA (µL) Volume of TE Buffer (µL) Final Volume (µL) 
100 0 1 µg/mL 
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Table 6: Continued 
Volume of λ DNA (µL) Volume of TE Buffer (µL) Final Volume (µL) 
50 50 500 ng/mL 
25 75 250 ng/mL 
10 90 100 ng/mL 
5 95 50 ng/mL 
1 99 10 ng/mL 
1 99 1 ng/mL** 
0 100 0 ng/ml 
 
** To make the 1 ng/ml dilution, diluted the diluted stock of λ DNA an additional 1:10 
with TE buffer. Then added 1µL of the newly diluted stock to the three wells that corresponded 
to the 1ng/ml well.  
 
Table 7. Volumes Added to Make Pico Green Solution 
Pico Green (µL) TE buffer (mL) Final Volume (mL) 
162.5 32.3375 32.5 
 
Fifth, 100 µL of the Pico Green solution was added to each well of the microtitre plate 
containing the λ DNA and the microtitre plate containing the sample DNA. After adding the 
PicoGreen mix, both plates were covered with foil and fluorescence was read on an HBJ 
BioSystems machine. 
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2.5 FLUORESCENT POLARIZATION 
2.5.1 FLUORESCENT POLARIZATION OVERVIEW 
Fluorescent polarization (FP) is a template-directed, primer extension assay that uses fluorophore 
labeled dideoxy-nucleoside triphosphates (ddNTPs), a primer (referred to as internal primer or 
IP) and a DNA polymerase. The IP is annealed one base pair upstream of the polymorphic site 
and in the presence of DNA polymerase and fluorophore labeled ddNTPs, the IP is extended by 
one base that is complementary to the mutation site. The alleles present in the target DNA can be 
inferred by the ddNTP that is incorporated. FP is based on the idea that when a fluorescent 
molecule is excited by plane-polarized light, the molecule itself will also emit polarized light. 
The FP of a molecule is proportional to the molecule’s rotational relaxation time, which is the 
time it takes to rotate through an angle of 68.5º.  The rotational relaxation time is directly 
proportional to the viscosity of the solvent, absolute temperature, and molecular weight of what 
of the fluorescent molecule. If viscosity and temperature are held constant then the FP is directly 
proportional to molecular weight.  If the molecule is small it will have lower molecular weight 
and will therefore tumble faster and emission of light will be depolarized. Likewise, if the 
molecule is large it will have a higher molecular weight and will therefore tumble slower and 
light emission will remain polarized. FP is expressed as the ratio of fluorescent detected in the 
vertical and horizontal axes for each dye and as a result it is independent of fluorescent intensity.  
[27, 28]. Fluorescence polarization was measured using LJL Biosystems Analyst HT.  Samples 
were plotted on a graph based on their mP value for each dye and their genotype will be 
determined based on combinations of mP values.  Samples with a high mP for only one dye were 
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genotyped as homozygous for that dye’s allele, while samples with high mP values for both dyes 
were heterozygous for the SNP. FP is done in three steps: Polymerase Chain Reaction (PCR) 
Amplification of DNA, Degradation and Single Base Extension [27-29].  
 
2.5.2 PCR AMPLIFICATION OF DNA 
Polymerase Chain Reaction (PCR) is an enzymatic dependent invitro method for amplifying 
specific segments of DNA [30]. PCR is performed in three steps: (1) denaturation of the double 
stranded DNA template into single strands; (2) the annealing of primers to each of the single 
strands for new strand synthesis; and (3) extension of the new DNA strands from the primers 
[31]. The reagents needed to carry out a PCR reaction are a DNA polymerase, Magnesium 
Chloride (MgCl2), 10x buffer without MgCl2, primers, deoxynucleotides (dNTPs) and sterile 
deionized water (SDW). Taq Polymerase, MgCl2 and the 10x buffer were all purchased from 
Sigma.  The sequence of the PCR primers used for each SNP can be seen in Table 8. The dNTPs 
were purchased from New England BioLabs. The deoxynucleotide solution set contained four 
separate solutions (one for each dNTP) at 0.25 ml of 100 mM ultrapure nucleotide. A dNTP mix 
was made by adding 20 µL of each dNTP into a 0.2 µL tube. For all plates the master mix was 
first made and then 10 µL of the master mix was aliquoted into each individual well. The DNA 
was then added to each well using an eight channel pipette. For each well of every plate, 2.5 µL 
of DNA was added. The master mix and DNA were added in this order to eliminate the 
possibility of contamination. The reaction mixture used for each 96 well plate and specific SNP 
can be seen in tables 9-14. The reaction was run in a Genemate 96 well 0.2 mL PCR low profile 
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flat plate purchased from ISC Bioexpress. The specific PCR program that was used for each 
plate is as follows: 
95º C for 2 minutes 
95º C for 30 seconds 
63º C for 30 seconds 
The temperature was increased by 3 º/s until 72 º C 
72 º C for 30 seconds 
Steps 2-5 were repeated 13 times. 
95 º C for 30 seconds 
56º C for 30 seconds 
72º C for 30 seconds 
Steps 6-8 were repeated 21 times 
 
Table 8. Sequences of PCR Primers 
PCR Primer Sequences 
SNP Forward Primer Reverse Primer 
rs2243113 CCCACCCTGTGTTCTCCATACTG AACAAGCAGGCATTAGACCGC 
rs2243140 TGAGTGGCAGGTGAGCAAGTATTAC GGGCAAAGATAGTTTCGGGATG 
rs383483 TGGAGCACTGGTTTTGGAGTCC GGGAGGGGATAGTAACTTTTGGGTC 
rs429774 TGCTCCACTTGCTCCAGGAACTTC TGCGGACCTCAGGATGATGATAC 
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Table 9. PCR Reaction Mixture for rs2243113 for plate 1. 
PLATE 1 
REAGENT PER CELL VOLUME  (µL)  
 
 
 
x 100 
MASTER MIX VOLUME  (µL) 
10x buffer 1.10 110 
MgCl2 1.25 125 
dNTPs 0.05 5 
PRIMERS 0.10 10 
TAQ 0.15 15 
SDW 7.35 735 
 
Table 10. PCR Reaction Mixture for rs2243113 plates 2-8 
PLATE 2-8 
REAGENT PER CELL VOLUME  (µL)  
 
 
 
x 100 
MASTER MIX VOLUME  (µL) 
10x buffer 1.10 110 
MgCl2 1.25 125 
dNTPs 0.05 5 
PRIMERS 0.10 10 
TAQ 0.10 10 
SDW 7.40 740 
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Table 11. PCR Reaction Mixture for rs2243140, plate 1 
PLATE 1 
REAGENT PER CELL VOLUME  (µL)  
 
 
 
x 100 
MASTER MIX VOLUME  (µL) 
10x buffer 1.10 110 
MgCl2 1.25 125 
dNTPs 0.05 5 
PRIMERS 0.10 10 
TAQ 0.15 15 
SDW 7.35 735 
 
Table 12.  PCR Reaction Mixture for rs2243140, plates 2-8 
PLATES 2-8 
REAGENT PER CELL VOLUME  (µL)  
 
 
 
x 100 
MASTER MIX VOLUME  (µL) 
10x buffer 1.10 110 
MgCl2 1.25 125 
dNTPs 0.05 5 
PRIMERS 0.10 10 
TAQ 0.10 15 
SDW 7.40 740 
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Table 13. PCR Mixture for rs429774, plate 1 
PLATE 1 
REAGENT PER CELL VOLUME  (µL)  
 
 
 
x 100 
MASTER MIX VOLUME  (µL) 
10x buffer 1.10 110 
MgCl2 1.25 125 
dNTPs 0.05 5 
PRIMERS 0.10 10 
TAQ 0.15 15 
SDW 7.35 735 
 
Table 14. PCR Mixture for rs429774, plates 2-8 
PLATES  2-8 
REAGENT PER CELL 
VOLUME  (µL) 
 
 
 
 
x 100 
MASTER MIX 
VOLUME  (µL) 
10x buffer 1.10 110 
MgCl2 1.25 125 
dNTPs 0.05 5 
PRIMERS 0.10 10 
TAQ 0.10 15 
SDW 7.40 740 
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2.5.3 GEL ELECTROPHORESES 
 
After the PCR product, we ran 1 µL of the PCR product on a gel to verify that the DNA 
amplification was successful. We used 1 µL of 2x dye mixed with 1 µL of our PCR product to 
run on the gel. Our agarose gels were made by heating 5 g of agarose into 250 mL of TE buffer. 
After all of the agarose was dissolved into the buffer, the mixture was allowed to cool. Then 12.5 
µL of ethidium bromide (EtBr) was added to the mixture. The mixture was poured into a loading 
tray and allowed to solidify for 30 minutes. A solution of 300 µL of TE buffer and 15 µL of EtBr 
was added to the loading tray. The gel was then added into the loading tray. Using an 8 channel 
pipette, the DNA was added to the gel. The gel ran at 100 volts for 30 minutes. 
 
2.5.4 DEGRADATION 
The degradation step of the FP is used to degrade excess dNTPs and unincorporated 
primers. 1 µL of rapid alkaline phosphatase (Roche), 0.05 µL of EXOI and 0.1 µL of 10x rap 
buffer was added to each individual well. A master mix was made and a multi-dispensing pipette 
was used to dispense 10 µL of the master mix into each well. The volumes used for each reagent 
can be seen in table The reaction was run in a genemate 0.2 mL 96 well low-profile PCR plate 
(purchased from ISC BioExpress) for total of 75 minutes. The first 60 minutes was run at 37º C 
and the last 15 minutes was run at 85ºC. 
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 Table 15. Reaction Volumes Used for Degradation Step. 
REAGANT 
PER CELL 
VOLUME (µL) 
 
 
 
x 100 (for the 
master mix) 
MASTER MIX 
VOLUME (µL) 
RAPID ALKALINE 
PHOSPHATASE 
0.1 100 
10X BUFFER 0.1 100 
EXO1 0.05 5 
SDW 7.95 795 
TOTAL 10 1000 
 
2.5.5 SINGLE BASE EXTENSION 
The single base extension step was done following the degradation step. A reaction using the 
forward internal primer and a separate reaction using the reverse internal primer were carried 
out. Primer sequences can be seen in Table 16. To avoid contamination, the reaction mixture was 
first made and then added to a 96 well, skirted, black twin tec PCR plate with yellow/black wells, 
purchased from Eppendorf, using a multi dispenser pipette. 5 µL was added to each individual 
well. 10 µL of the degraded-PCR product was added to the respective well using an 8 channel 
pipette. The program used for all plates is as follows: 
94º C for 1 minute 
94º C for 10 seconds 
52º C for 30 seconds 
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Repeat steps 2 and 3 40 times 
72º C for 10 seconds 
 
Table 16.  Forward and Reverse Internal Primer Sequences 
FP Internal Primer Sequences 
SNP Internal Primer (Forward) Internal Primer (Reverse) 
rs2243113 AAGACTCCCCACTACTCTCAGCAC TGCCATACTAAGGAGTGTACTTTC 
rs2243140 ATGCTCCTTATAAGAATCTAAGTAA CTGTTCCACCTCGTATTATCAGGC 
rs383483 GCTAATGCGTAACCCTTGTCCAGC CCAAGTCTTTTTATTGGGTGCACA 
rs429774 GGCACCAGTCACTTAACCATCAT TACACAGTTGGAGCTCAATAAGC 
 
Table 17. Single Base Extension Reaction Mixture 
REAGENT VOLUME PER 
CELL (µl) 
 
 
 
 
 
x 100 (for master 
mix) 
MASTER MIX 
VOLUME (µL) 
THERMO 
SEQUENASE 
0.05 5 
10x BUFFER 0.5 50 
DYE LABLED 
ddNTPs 
0.025 2.5 
INTERNAL 
PRIMER 
0.5 5 
SDW 3.925 392.5 
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3.0  STATISTICAL METHODS 
3.1 HARDY-WEINBERG PRINCIPLE 
The Hardy-Weinberg Principle (HWP) asserts that under specific conditions the allele and 
genotype frequencies of a particular population remain constant when certain assumptions are 
met. This equilibrium is maintained from generation to generation unless those assumptions 
about the population are disturbed. The main assumptions made under the HWP are: 
1. Diploid organisms 
2. Sexual reproduction 
3. Non-overlapping generations 
4. Random mating 
5. Large population size 
6. Equal allele frequencies in the sexes 
7. No mutation  
8. No selection 
With these assumptions, the genotype frequencies for a biallelic gene can be calculated 
using the Hardy-Weinberg Equation [32]. 
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3.2 HARDY-WEINBERG EQUATION 
 
The Hardy-Weinberg Equilibrium (HWE) is a theoretical method which describes and predicts 
genotype and allele frequency in a given population. HWE enables the actual genetic make up of 
a population to be compared to what is expected to be seen under the Hardy-Weinberg Principle. 
The Hardy-Weinberg Principle asserts that under specific conditions the allele and genotype 
frequency of a particular gene remain constant. The Hardy-Weinberg equation takes the 
following the form: 
p2 + 2pq + q2 = 1 
where p2 is homozygous for one allele (AA), 2pq is heterozygous for two different alleles (Aa) 
and q2 is homozygous for the second allele (aa) [32]. The total number of alleles must be 
calculated in order to perform the HWE. These values are then used to compute the expected 
values. Once the observed alleles were obtained, these values were used to calculate the p2, q2 
and 2pq values [32]. The observed and expected values can be placed into a contingency table 
(Table 18): 
Table 18. Example of Chi Squared Contingency Table 
ALLELE OBSERVED EXPECTED 
AA OAA EAA 
GG OGG EGG 
GA OGA EGA 
TOTAL OAA + OGG + OGA EAA + EGG + EGA 
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3.3 STATISTICAL TESTS 
3.3.1 CHI-SQUARED TEST OF INDEPENDENCE 
For the overall data, the chi-squared (χ 2) test of independence was used to determine if the 
expected values were significantly different from the observed values. The χ2 test statistic is 
calculated by the following formula: 
 
∑ 




 −
=
e
eo 22 )(χ
 
 
The null (H0) and alternative (H1) hypotheses were set as the following: 
  H0: There is no significant difference between observed and expected values 
Ha: There is a significant difference between observed and expected values 
 
We set our alpha as (α) = 0.05 and our degrees of freedom (df) as one. Under the χ2 distribution, 
the χ2 critical value for α = 0.05 and one degree of freedom is 3.94. Any statistic found that is 
equal or less than 3.94 would lead to a failure to reject H0. Any statistic found that is greater than 
3.94 would result in rejecting H0. 
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3.3.2 FAST EXACT HARDY-WEINBERG TEST FOR SNPS 
For the geographical distribution data and the stratified Kenya data, the sample sizes were small 
(< 5) so instead of using the χ2 test statistic, a fast exact Hardy-Weinberg Equilibrium test for 
SNPs (SNP-HWE) was performed using the R statistical software package version of SNP-HWE 
[33].  
The null (H0) and alternative (H1) hypotheses were set as the following: 
  H0: There is no significant difference between observed and expected values 
Ha: There is a significant difference between observed and expected values 
We set our p-value at 0.05; any value less than or equal to 0.05 we will reject H0 and any value 
greater than 0.05 we will fail to reject H0.  
3.4 HAPLOTYPE CONSTRUCTION 
 A haplotype is a profile of SNPs; it is the combination of SNP alleles on a particular gene or 
region of a gene. Because individuals have 2 copies of each gene, there are also 2 haplotypes for 
each combination of SNPs. We created haplotypes to enhance our allelic information because 
sometimes a single SNP is not sufficient to explain an observed phenotype. We used the PHASE 
software package to create haplotypes of the SNPs that are found on the same gene [34]. We 
constructed haplotypes for rs2243113 and rs2243140 which are both found on IL-12A and 
haplotypes for rs383483 and rs429774, which are both found on IL-12Rβ1. 
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4.0  RESULTS 
4.1 DESCRIPTION OF FP RESULTS 
We analyzed 4 SNPs, two in the gene encoding the p35 subunit of IL-12 and 2 in the gene 
encoding the β1 receptor of the IL-12 receptor. We genotyped the DNA samples for these SNPs 
using Fluorescent Polarization (FP). With Fluorescent Polarization (FP), the data is clustered into 
four groups: homozygous AA, homozygous GG, heterozygous GA or blank. The mP values of 
the sample determine how that specific sample will be called. Samples that fall within the mP 
value range for  homozygous AA will be called ‘AA,’ samples that fall within the mP value 
range of GG will be called ‘GG’ and samples that fall within the mP values range of blank will 
be called ‘Blank’. We had samples that did not fall within those ranges and thus were unable to 
be called into any particular group. These data samples will be termed ‘No Call’. The ‘No Call’ 
samples are the samples that lie within the yellow and red bars on the scatter plot. An example of 
scatter plot readout can be seen in Figure 5. 
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Figure 5. Scatterplot readout of FP data. 
 
From the FP results we calculated the frequency of each genotype for each SNP. To do 
this the results from each 96 well plate added together. From this data, we compiled two tables: 
an overall genotype frequency and an informative genotype frequency. The overall genotype 
frequency table includes all the samples even if they were ‘Blank’ or ‘No Call’. The Informative 
Genotype Frequency Table includes only those samples that were called ‘AA’, ‘GG’ or ‘GA’. 
The total frequency of each genotype for each particular SNP can be seen Tables 19-26. 
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Table 19. Overall Genotype Frequency for rs2243113. 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
AA 95 14.1 
GA 271 40.3 
GG 9 1.3 
BLANK 97 14.4 
NO CALL 200 29.8 
TOTAL 672 100 
 
Table 20. Informative Genotype Frequencies for rs2243113 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
AA 95 25.3 
GA 271 72.3 
GG 9 2.4 
TOTAL 375 100 
 
Table 21. Overall Genotype Frequency for rs2243140 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
AA 126 26.3 
GA 38 7.9 
GG 141 29.4 
BLANK 100 20.8 
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Table 21: Continued 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
NO CALL 75 15.6 
TOTAL 480 100 
 
Table 22. Informative Genotype Frequency for rs2243140 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
AA 126 41.3 
GA 38 12.5 
GG 141 46.2 
TOTAL 305 100 
 
Table 23. Overall Genotype Frequency for rs383483 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
TT 49 6 
TC 23 12.8 
CC 96 25 
BLANK 126 32.8 
NO CALL 87 22.7 
TOTAL 672 100 
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Table 24. Informative Genotype Frequency for rs383483 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
TT 49 29.2 
TC 23 13.7 
CC 96 57.1 
TOTAL 168 100 
 
Table 25. Overall Frequency for rs429774 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
AA 256 38.3 
GA 81 12.1 
GG 55 8.2 
BLANK 173 25.9 
NO CALL 103 15.4 
TOTAL 668 100 
 
Table 26. Informative Genotype Information for rs429774 
GENOTYPE FREQUENCY PERCENTAGE OF SAMPLES (%) 
TT 256 65 
TC 81 21.1 
CC 55 14 
TOTAL 394 100 
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4.2 HARDY-WEINBERG AND CHI-SQUARED TEST 
4.2.1 OVERALL HWE AND CHI-SQUARED TEST RESULTS 
We used the Hardy-Weinberg Equilibrium (HWE) to compare the genotypic makeup of 
our samples to what we would expect to see under the Hardy-Weinberg Principle. We calculated 
the frequency of A, G, C or T alleles for each specific SNP. This information can be observed in 
Tables 27-30.   
Table 27.  Allele Frequency For rs22431113 
ALLELE OBSERVED FREQUENCY 
A 451 
G 289 
TOTAL 740 
 
Table 28. Allele Frequency For rs2243140 
ALLELE OBSERVED FREQUENCY 
A 290 
G 320 
TOTAL 610 
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Table 29. Allele Frequency for rs383483 
ALLELE OBSERVED FREQUENCY 
T 121 
C 215 
TOTAL 336 
 
Table 30. Allele Frequency for rs22431113 
ALLELE OBSERVED FREQUENCY 
A 595 
G 193 
TOTAL 788 
 
 
 
We used the Hardy-Weinberg equation (p2 + 2pq + q2) in conjunction with our allele 
frequencies and observed number of genotype frequencies to calculate the values for p2, 2pq, and 
q2. We then used our p2, q2 and 2pq values to calculate our expected observations. To do this, we 
multiplied our observed total population by our p2, q2 and 2pq values. This data can be observed 
in the Tables 31-34. 
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Table 31. Observed and Expected Genotype Frequency for rs2243113 
GENOTYPE OBSERVED (O) EXPECTED (E) (O-E) (O-E)2 (O-E)2 / E 
AA 95 139.125 -44.125 1947 13.99 
GG 9 57.375 -48.375 2340 40.79 
GA 271 178.5 92.5 8556 47.93 
TOTAL 375 375  
 
Table 32. Observed and Expected Genotype Frequency for rs2243140 
GENOTYPE OBSERVED (O) EXPECTED (E) (O-E) (O-E)2 (O-E)2 / E 
AA 126 68.93 57.07 3256 47.25 
GG 141 83.875 57.13 3263 38.91 
GA 38 152.195 -114.20 13030 85.68 
TOTAL 305 305  
 
                       
Table 33. Observed and Expected Genotype Frequency for rs383483 
GENOTYPE OBSERVED (O) EXPECTED (E) (O-E) (O-E)2 (O-E)2 / E 
AA 49 21.84 27.16 737 33.77 
GG 96 68.712 27.29 744.63 10.84 
GA 23 77.448 -54.45 2964 38.27 
TOTAL 168 168  
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Table 34. Observed and Expected Genotype Frequency for rs429774 
GENOTYPE OBSERVED (O) EXPECTED (E) (O-E) (O-E)2 (O-E)2 / E 
AA 256 224.58 31.42 987 4.40 
GG 55 23.64 31.36 983 41.60 
GA 83 145.78 -62.78 3941 27.03 
TOTAL 394 394  
 
We then calculated our χ2 value by using the χ2 equation ( ∑ 




 −
=
e
eo 22 )(χ ). The values 
for these can be found in Table 35.   
 
Table 35. Calculated χ2 values for each SNP. 
SNP χ2 Value 
rs2243113 102.71 
rs2243140 171.84 
rs383483 82.88 
rs429774 73.3 
 
All of our calculated χ2 values are greater than 3.94 so we would reject H0 thus 
concluding that there is a significant difference between our observed and expected values.  We 
then used the HWE to determine if the difference that exists between our observed and expected 
values could be accounted for by the specific clinical statuses.  
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4.2.2 HWE AND SNP_HWE RESULTS BY DISEASE STATUS 
Observed and expected values for each SNP by the specific clinical disease status can be seen in 
Tables 36-40.  
SNP rs2243113 is a change from an A  G and rs2243140 is a change from a T  C 
and they are both been associated with a susceptibility to SMA. Although we saw a significant 
difference between the observed and expected values within each clinical status we did not see a 
significant difference between each status. Looking at the graphical representations (Figures 6 
and 7) we can see that each disease group follows the same trend. If this SNP was a playing a 
role in susceptibility to SMA, we would only expect to see a higher frequency of the 
homozygous mutant genotype and a deviation from HWE in the SMA disease group. We can 
conclude that for our particular population rs2243113 and drs2243140 do not display a 
susceptibility to SMA. 
SNP rs383483 has been shown to have a protective effect against SMA and HDP and 
rs429774 has been shown to have a protective effect for SMA. SNP rs383483 is a change from a 
G  A and rs429774 is a change from a C  T; rs383483 has been associated with a protection 
against SMA and HDP and rs429774 has been associated with a protection against SMA. For 
rs429774 and rs383483 (HDP protection) we observed a significant difference between the 
observed and expected values within each disease group, but between each group there is not a 
difference (Figures 8 – 10). If this SNP was playing a protective role, we would expect to see a 
higher frequency of the homozygous mutant genotype and a deviation from HWE in the non-
SMA disease groups. We can conclude that for our population, SNP rs383483 does not play a 
protective role against SMA and HDP and SNP rs429774 does display a protection against SMA.  
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Table 36. Observed and Expected Values and Corresponding p-values for Anemia Status by Genotype – rs2243113 
rs2243113 Anemia Status by Genotype 
Non-Anemic 
Genotype Observed Expected p-value 
AA 8 13 
0.0005 AG 26 16 
GG 0 5 
Mild Malaria Anemia 
Genotype Observed Expected p-value 
AA 34 45 
4.86e-8 AG 67 45 
GG 0 11 
Moderate Malaria Anemia 
Genotype Observed Expected p-value  
AA 23 31 
2.93e-6 AG 49 17 
GG 0 8 
Severe Malaria Anemia 
Genotype Observed Expected p-value 
AA 18 24 
0.002 AG 41 29 
GG 3 9 
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Figure 6. Observed and Expected Values for Anemia Status by Genotype – rs2243113 
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Table 37. Observed and Expected Values and Corresponding p-values for Anemia Status by Genotype –rs22431140 
rs2243113 Anemia Status by Genotype 
Non-Anemic 
Genotype Observed Expected p-value 
TT 10 4 
1.08e-6 TC 2 14 
CC 19 13 
Mild Malaria Anemia 
Genotype Observed Expected p-value 
TT 41 22 
6.43e-15 TC 13 50 
CC 47 28 
Moderate Malaria Anemia 
Genotype Observed Expected p-value  
TT 27 13 
4.78e-13 TC 8 35 
CC 37 23 
Severe Malaria Anemia 
Genotype Observed Expected p-value 
TT 31 20 
1.91e-8 TC 11 33 
CC 25 14 
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Figure 7. Observed and Expected Values for Anemia Status by Genotype – rs2243140 
 
Table 38. Observed and Expected Values and Corresponding p-values for Anemia Status by Genotype –rs383483 
rs383483 Anemia Status by Genotype 
Non-Anemic 
Genotype Observed Expected p-value 
GG 9 6 
0.0006 GA 3 11 
AA 10 5 
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Table 38: Continued 
Mild Malaria Anemia 
Genotype Observed Expected p-value 
GG 29 20 
1.35e-6 GA 9 26 
AA 17 8 
Moderate Malaria Anemia 
Genotype Observed Expected p-value  
GG 27 19 
3.65e −7 GA 5 20 
AA 13 5 
Severe Malaria Anemia 
Genotype Observed Expected p-value 
GG 25 22 
0.002 GA 5 12 
AA 5 2 
 
 
48 
 
    
Figure 8. Observed and Expected Values for Anemia Status by Genotype – rs383483 
 
Table 39. Observed and Expected Values and Corresponding p-values for Parasitemia Status by Genotype -
rs383483 
rs383483 Anemia Status by Genotype 
Aparasitemic 
Genotype Observed Expected p-value 
GG 18 11 
3.15e −6 GA 7 17 
AA 10 6 
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Table 39: Continued 
Low Density Parasitemia 
Genotype Observed Expected p-value 
GG 48 34 
9.3e −12 GA 9 36 
AA 23 9 
High Density Parasitemia 
Genotype Observed Expected p-value  
GG 24 19 
0.0006 GA 8 17 
AA 9 4 
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Figure 9.Observed and Expected Values for Parasitemia Status by Genotype – rs383483 
 
Table 40. Observed and Expected Values and Corresponding p-values for Anemia Status by Genotype 
rs429774 Anemia Status by Genotype 
Non-Anemic 
Genotype Observed Expected p-value 
CC 10 4 
0.0002 CT 10 21 
TT 32 26 
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Table 40: Continued 
Mild Malaria Anemia 
Genotype Observed Expected p-value 
CC 19 9 
3.62e-6 CT 25 45 
TT 69 59 
Moderate Malaria Anemia 
Genotype Observed Expected p-value  
CC 12 4 
2.08e-5 CT 17 32 
TT 66 58 
Severe Malaria Anemia 
Genotype Observed Expected p-value 
CC 15 6 
5.28e-6 CT 18 36 
TT 60 51 
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Figure 10. Observed and Expected Values for Anemia Status by Genotype – rs429774 
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4.3 HAPLOTYPE CONSTRUCTION 
A haplotype is a combination of SNP alleles on a particular gene or region of a gene. Because 
individuals have two copies of each gene, there are also two haplotypes for each combination of 
SNPs. We created haplotypes to enhance our allelic information because sometimes a single SNP 
is not sufficient to explain a particular phenotype. Data for each haplotype can be seen in Tables 
40 – 43 and graphical representations can be seen immediately following (Figures 11-14). The 
haplotypes for IL-12 consist of SNPs rs2243113 and rs2243140, both of which have been 
associated with a susceptibility to SMA. The haplotypes for IL-12Rβ1 consists of SNPs 
rs383483 and rs429774, both of which have been associated with a protection against SMA. 
Although rs383483 has also been associated with a protection against HDP, we only looked 
SMA because rs429774 has not been shown to be protective for HDP.  For all of the haplotypes, 
there was not one that was either more prevalent in the less severe anemia status as compared to 
the SMA group or more prevalent in the SMA disease groups compared to the less severe disease 
group. Because the haplotype data did not reveal any results that differed or help to explain the 
results of our Hardy-Weinberg results, we decided to not pursue any further testing.  
 
Table 41.  IL-12 Haplotypes for SNP Profile 1 
 Haplotype 
Disease Status AC AT GC GT 
Non-Anemic 0 11 17 7 
Mild Malaria Anemia 4 9 59 30 
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Table 41: Continued 
Disease Status AC AT GC GT 
Moderate Malaria Anemia 6 8 36 21 
Severe Malaria Anemia 7 23 29 20 
 
 
 
Figure 11. IL-12 SNP Profile 1 Haplotypes 
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Table 42. IL-12 Haplotypes for SNP Profile 2 
 Haplotype 
Disease Status AC AT GC GT 
Non-Anemic 27 8 0 0 
Mild Malaria Anemia 76 26 0 0 
Moderate Malaria Anemia 54 15 1 1 
Severe Malaria Anemia 61 17 1 0 
 
 
Figure 12. IL-12 SNP Profile 2 Haplotypes 
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Table 43. IL-12Rβ1 Haplotypes for SNP Profile 1 
 Haplotype 
Disease Status AC AT GC GT 
Non-Anemic 0 5 4 4 
Mild Malaria Anemia 4 16 5 18 
Moderate Malaria Anemia 2 9 8 7 
Severe Malaria Anemia 2 13 5 9 
 
 
   
Figure 13. IL-12Rβ1 SNP Profile 1 Haplotypes 
 
57 
 
Table 44. IL-12Rβ1 Haplotypes for SNP Profile 1 
 Haplotype 
Disease Status AC AT GC GT 
Non-Anemic 0 2 2 9 
Mild Malaria Anemia 1 15 4 23 
Moderate Malaria Anemia 1 10 6 9 
Severe Malaria Anemia 0 6 4 19 
 
 
 
Figure 14. IL-12Rβ1 SNP Profile 2 Haplotypes 
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4.4 DISTRIBUTION OF SNPS ACROSS DIFFERENT GEOGRAPHICAL REGIONS 
We investigated the distribution of SNPs rs2243113, rs2243140, rs383483 and rs429774 in 
different populations with varying malaria transmission rates. In addition to our Kenyan pediatric 
population, we also looked at the distribution of these SNPs in other populations.  Our additional 
populations include samples from Bogoin Village, Central African Republic, the Kavieng and 
Madang regions of Papua New Guinea, and the Betsileo, Merina, Bezanozano and Sihanaka 
tribes of Madagascar. Furthermore, we also took information from the International HapMap 
Project. The populations used from HapMap are the Yoruba in Ibadan, Nigeria (YRI), the 
Japanese in Tokyo, Japan (JPT), the Han Chinese in Beijing, China (CHB), and the CEPH 
Collection [(Utah Residents with Northern and Western European Ancestry)CEU][26]. Data for 
the HapMap populations are not available for every SNP; therefore the HapMap populations will 
not be the same for every SNP. Data for rs2243113 does not have all of the populations due 
toissues with genotyping. 
 These populations vary in the rate of malaria transmission. With the exceptions of the 
JPT, CHB, CEPH, Merina and Betsileo populations, all of the populations are found in areas 
where malaria is endemic and transmission is stable (Figure 15). For the JPT population and 
Merina populations, malaria is not a risk. The malaria risk for the Betsileo population ranges 
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from no transmission to marginal transmission. We genotyped DNA samples and used the R 
version of SNP-HWE to determine if a significant difference exist between our genotyped data 
and what would be expected under the Hardy-Weinberg equilibrium. The p-value for each 
population for each SNP can be seen in Tables 45 – 48. 
 
Country Population Stable Marginal No Risk 
Kenya W. Kenya       
Central African Republic Bogoin Village       
Papua New Guinea Kavieng       
Madang       
Madagascar 
Betsileo       
Merina       
Bezanozano       
Sihanaka       
HapMap 
YRI       
JPT       
CHB       
CEU       
pgaAA       
pgaEUR       
 
Figure 15.Transmission rates for each population are indicated by a red block. 
 
Table 45. Calculated p-values by Population – rs2243113 
p-values by Population – rs2243113 
Population p-value 
Kenya 6.17e −28 
Betsileo 0.048 
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Table 45: Continued 
Population p-value 
Merina 0.269 
Kavieng 0.0006 
Madang 0.0006 
YRI 0 
AA 5.2e −13 
 
 
Table 46. Calculated p-values by Population – rs2243140 
p-values by Population – rs2243140 
Population p-value 
Kenya 3.83e −18 
Betsileo 0.013 
Merina 1.03e −8 
Bezanozano 0.091 
Sihanaka 0.014 
Bogoin Village 0.001 
Kavieng 2.32e −6 
Madang 1.24e −14 
HCB 7.00e −5 
JPT 4.31e −7 
YRI 6.62e −5 
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Table 46: Continued 
Population p-value 
AA 0.100 
EURO 0.062 
 
 
Table 47. Calculated p-values by Population – rs383483 
p-values by Population – rs383483 
Population p-value 
Kenya 0.039 
Betsileo 0.616 
Merina 0.0002 
Bezanozano 1 
Sihanaka 1 
Bogoin Village 6.15e −9 
Kavieng 2.32e −6 
Madang 1.24e −14 
 
Table 48. Calculated p-values by Population – rs429774 
p-values by Population – rs429774 
Population p-value 
Kenya 3.79e −9 
Betsileo 0.543 
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Table 48: Continued 
Population p-value 
Merina 1.57e −5 
Bezanozano 1 
Sihanaka 0.009 
Bogoin Village 3.28e −12 
Kavieng 0.137 
Madang 0.051 
CEU 7.06e −9 
HCB 2.83e −6 
JPT 0 
YRI 4.63e −16 
 
 
 
For rs2243113, which has been associated with a susceptibility to malaria, the Merina 
population is the only population in which there is not a deviation from the Hardy-Weinberg 
Equilibrium (HWE). The Merina population is the only population that does not have a risk for 
malaria transmission, which suggests that there may be some selection for rs2243113 in the 
populations that are at risk for malaria.  For rs2243113, all the populations excluding the Kenya 
population have a higher genotype frequency for the ‘AA’ genotype which is the homozygous 
wildtype genotype (Figure 16). For rs2243140, a deviation from HWE was found in all 
populations except the Bezanozano, AA and EURO. The deviation from HWE cannot be 
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explained by rates of transmission because the deviation exists in all transmissions rates. When 
compared to the Kenyan population all of the additional populations have a higher frequency of 
the ‘TT’ genotype which is the homozygous wildtype genotype (Figure 17). For rs383483, which 
has been associated with a protection against SMA and HDP, a deviation from HWE exists in all 
populations except for the Betsileo, Bezanozano and Sihananka. Similar to rs2243140, this 
deviation cannot be attributed to transmission rate because it also occurs in areas of varying 
transmission rate. The populations that did not have the deviations were in areas of no, marginal 
and stable transmission rates. When comparing the Kenyan population to the other populations, 
there is a higher frequency of the heterozygous genotype in all populations except for the 
Kenyan population. For rs429774, which has been associated with a protection against SMA, 
there is a deviation from HWE in all populations except the Betsileo, Bezanozano, Kavieng, 
Madang and JPT. Again, this deviation or lack of deviation can not be attributed to the rates of 
malaria transmission because of the occurrence in all levels of transmission. Unlike the previous 
three SNPs, a general trend does not exist for the additional populations when compared to the 
Kenyan population. However, when broken down by country, a trend does exist. For the Kavieng 
and Madang populations, which are both in Papua New Guinea, there appears to be an almost 
equal distribution of the genotypes. For the four tribes of Madagascar; the Betsileo, The 
Bezanozano, the Sihanaka and the Merina there is a higher frequency of the ‘TT’ genotype, 
which is the homozygous mutant genotype.  
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Figure 16. Distribution of rs2243113 Across Different Populations 
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Figure 17. Distribution of rs2243140 Across Different Populations 
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Figure 18. Distribution of rs383483 Across Different Populations 
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Figure 19. Distribution of rs429774 Across Different Populations 
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5.0  DISCUSSION 
In the process of genotyping, significant difficulties were experienced; in some cases we 
lost more than 50% of our samples due to the inability to genotype. There are several possible 
explanations to account for this. To ensure that the fluorescent polarization (FP) assay was not 
the issue, we tried the TaqMan assay, which yielded either the same results or in most cases 
worse results (data not shown). The FP assay results can only be as good as the starting material. 
A lot of our samples were taken from children under the age of 3 who had malaria. Because of 
the complication of anemia that results from malaria, a small blood sample was taken, from 
which DNA was extracted. Due to the initial amount of extracted genomic DNA being so small, 
all of our samples are Wholoe-Genome Amplified. Because our samples have been stored for 
over 5 years, it is also possible that the DNA concentration may have altered due to evaporation. 
Unidentified SNPs located in the primer region or in the stretch of DNA that is being amplified 
for genotyping could also account for failed or ambiguous samples. If there is an unaccounted for 
SNP in a primer site (SNP-in-primer) and it has a high minor allele frequency, and it is in linkage 
disequilibrium with the target SNP or has an effect on the hybridization of the primers than the 
genotyping failure rate could increase [35].  
Copy Number Variation (CNV) is a phenomenon that happens in chromosomal 
rearrangement and results in a deletion or duplication of stretches of DNA sequences. There are 
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several ways to check or account for these factors. One would be to sequence the samples to see 
if there are any additional mutations. A second method would be to perform an assay that checks 
for CNV such as multiplex amplifiable probe hybridization (MAPH) or multiplex ligation-
dependent probe amplification (MLPA). It would also be plausible to compile a new set of 
samples and genotype the samples to see if the results are the same.  
Geographically, we observed a higher frequency of the homozygous mutant genotype in 
all populations except the Kenyan population for SNPs rs2243113 and rs2243140. Our Kenyan 
population is made up of children whereas the other populations were all comprised of adults. 
Severe disease complications and death from malaria occur mostly in children. It is a possibility 
that in our additional populations we see more of the homozygous wildtype genotype for 
rs2243113 and rs2243140 because of selection bias.  Specifically, the individuals chosen from 
the non-Kenyan populations were adults and it is possible that they survived the increased risks 
that are present during childhood. To control for this bias, a good study would be to sample a 
pediatric population and adult population from the same area of Kenya and see if the results hold 
true for the adult population.  
Although it is known that these SNPs do not alter the amino acids in the protein products, 
it is unknown what effect these SNPs could be having on IL-12 or IL-12R. Gene expression 
assays could be done to assess whether there is an increase or decrease in gene expression. For 
SMA, it is possible that an increase in the expression of IL-12 could be the cause. For every 
infected red blood cell (iRBC) that is destroyed, ten uninfected RBCs are removed from 
circulation, a process in which  macrophages play an important role [15]. If the levels of IL-12 
are increased, then the amount of IFN-γ induced by IL-12 will also increase. An increased 
amount of IFN-γ will prime that much more monocytes thereby increasing the levels of 
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macrophages which help to contribute to the removal of uninfected RBCs. It has also been 
shown that IFN-γ plays a role in the mechanisms of bone marrow depression and 
dyserythropoiesis [36].  An increase in the IL-12 receptor would also have this same effect 
because it would work by the same mechanism of increasing the amount of IFN-γ and 
monocytes. A decrease in IL-12 could be the cause of HDP. If the expression of IL-12 is 
decreased, then the immune response to the malaria infection would be less than optimal. 
Decreased levels of IL-12 would also result in decreased levels of T-cells, NK-cells, 
macrophages and dendritic cells. This would result in a decreased removal of iRBCs and of 
parasites. A decrease in the IL-12 receptor would also display the same results. If there is a 
decrease in the receptor, the response to IL-12 would also decrease thereby creating the same 
less than optimal immune response.  
The purpose of this study was to determine if there was a correlation between the disease 
status of either high density parasitemia (HDP) and/or severe malaria anemia (SMA) and SNPs 
rs2243113, 2243140 rs33483 and rs429774. We used the Hardy-Weinberg Equilibrium and 
either the Chi-Squared Test statistic or the R version of SNP-HWE to determine if the genotypic 
makeup of our population was what would be expected under the Hardy-Weinberg Principle.  
For all SNPs we found that there is a significant difference between our observed and expected 
values for the overall population. In addition, when the population was broken down by disease 
status, we found that a significant difference existed for our observed and expected values for all 
disease statuses. There was no difference between disease groups, which led us to conclude that 
SNPs rs2243113 and rs2243140 do not display a susceptibility to SMA. Likewise, we concluded 
that rs383483 does not display a protection against SMA or HDP and rs429774 does not display 
a protection against SMA. We also created haplotypes, which are combinations of SNP alleles on 
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a particular gene. However, our haplotypes did not increase our information because there was 
not any haplotype that was more prevalent in either the less severe disease complications as 
opposed to the more severe disease complications and vice versa. We found that for all four 
SNPs -rs2243113, rs224310, and rs429774 - there was not a correlation between disease status 
and genotype. We also investigated the distribution of these four SNPs across populations with 
varying malaria endemicity. We also found that in all of the populations except for the Kenyan 
population there is a higher frequency of homozygous wildtype alleles for both rs2243113 and 
rs2243140 and a higher frequency of heterozygotes for rs383483.  
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APPENDIX 
GENOTYPE DISTRIBUTION ACROSS DIFFERENT POPULATIONS 
The following charts are the ‘percent of observations’ by genotype for each population. It should 
be noted that the ‘n’ category in these charts does not represent the total sample size; it only 
represents the number of samples that were genotyped and able to be called the respective 
genotype.  
Table 49. Distribution of rs2243113 Across Several Populations 
 Genotype Frequency (%) 
Population n wt/wt (AA) wt/mt (AG) mt/mt (GG) 
Western Kenya 294 32.3 65.6 2.0 
Betsileo 22 68.18 31.18 0 
Merina 22 50 50 0 
Kavieng 24 83.33 16.67 0 
Madang 47 65.96 24.04 0 
YRI 60 73.3 18.3 8.3 
AA 60 93.5 6.5 0 
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Table 50. Distribution of rs2243140 Across Several Populations 
 Genotype Frequency (%) 
Population n wt/wt (TT) wt/mt (TC) mt/mt (CC) 
Western Kenya 305 41.3 12.5 46.2 
Betsileo 31 74.19 12.90 12.90 
Merina 30 100 0 0 
Bezanozano 11 81.82 9.09 9.09 
Sihanaka 12 91.67 0 8.33 
Bogoin Village 41 68.29 31.71 0 
Kavieng 22 100 0 0 
Madang 50 100 0 0 
HCB 44 79.5 20.5 0 
JPT 45 86.7 11.1 2.2 
YRI 57 75.4 22.8 1.8 
AA 24 70.8 25 4.2 
EURO 23 60.9 39.1 0 
 
 
Table 51. Distribution of rs383483 Across Several Populations 
 Genotype Frequency (%) 
Population n wt/wt (GG) wt/mt (GA) mt/mt (AA) 
Western Kenya 168 57.1 13.7 29.2 
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Table 51: Continued 
  Genotype Frequency (%) 
Population n wt/wt (GG) wt/mt (GA) mt/mt (AA) 
Betsileo 14 42.86 28.57 28.57 
Merina 27 14.81 51.85 33.33 
Bezanozano 7 28.57 71.43 0 
Sihanaka 9 55.56 44.44 0 
Bogoin Village 29 0 62.07 37.93 
Kavieng 20 20 35 45 
Madang 50 100 0 0 
 
 
Table 52. Distribution of rs429774 Across Several Populations 
 Genotype Frequency (%) 
Population n wt/wt (CC) wt/mt (CT) mt/mt (TT) 
Western Kenya 394 14 21.1 65 
Betsileo 16 43.75 0 56.25 
Merina 27 7.41 29.63 62.96 
Bezanozano 8 25 0 75 
Sihanaka 10 0 20 80 
Bogoin 49 4.08 51.02 44.90 
Kavieng 17 29.41 41.18 29.41 
Madang 36 33.33 38.89 27.78 
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Table 52: Continued 
  Genotype Frequency (%) 
Population n wt/wt (CC) wt/mt (CT) mt/mt (TT) 
CEU 60 13.6 47.5 39 
HCB 45 15.6 44.4 40 
JPT 45 13.3 48.9 37.8 
YRI 60 1.7 36.7 61.7 
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